🕷️ Crawler Inspector

[    ](https://pharmaniaga.com/) - [About Us](https://pharmaniaga.com/) - [Who We Are](https://pharmaniaga.com/about-us/who-we-are/) - [Corporate Policies](https://pharmaniaga.com/about-us/corporate-policies/) - [Corporate Structure](https://pharmaniaga.com/about-us/corporate-structure/) - [Leadership](https://pharmaniaga.com/about-us/leadership-2/) - [Milestones](https://pharmaniaga.com/milestones/) - [Awards & Recognitions](https://pharmaniaga.com/about-us/awards-recognitions/) - [Standards & Certifications](https://pharmaniaga.com/standards-certifications/) - [Products & Services](https://pharmaniaga.com/) - [Products](https://pharmaniaga.com/) - [Pharmaceutical](https://pharmaniaga.com/product/pharmaceutical-3/) - [Services](https://pharmaniaga.com/services/) - [Logistics & Distribution](https://pharmaniaga.com/services/logistics-and-distribution/) - [Manufacturing](https://pharmaniaga.com/services/manufacturing/) - [Medical Equipping](https://pharmaniaga.com/services/medical-equipping/) - [Research & Development](https://pharmaniaga.com/services/research-and-development/) - [Customer Care](https://pharmaniaga.com/customer-care) - [Indonesia Operation](https://pharmaniaga.com/services/indonesia-operations-2/) - [Distributorship](https://pharmaniaga.com/distributorship) - [Approved Products Purchased List](https://catalogv2.pharmaniaga.com/) - [Investor Relations](https://pharmaniaga.com/investor-relations-2/) - [Corporate Information](https://pharmaniaga.com/investor-relations-2/corporate-information/) - [Corporate Governance](https://pharmaniaga.com/investor-relations-2/corporate-governance-2/) - [Stock Information](https://pharmaniaga.com/investor-relations-2/stock-information/) - [Financial Information](https://pharmaniaga.com/investor-relations-2/financial-information/) - [Investor Resources](https://pharmaniaga.com/investor-relations-2/investor-resources/) - [News Centre](https://pharmaniaga.com/investor-relations-2/news-centre/) - [Reports](https://pharmaniaga.com/investor-relations-2/reports/) - [Sustainability](https://pharmaniaga.com/sustainability/) - [ESG Profile](https://bit.ly/3v5ldxl) - [Our Sustainability Missions](https://pharmaniaga.com/sustainability/#our-sustainability-mission) - [Sustainability Roadmap](https://pharmaniaga.com/sustainability/#sustainability-roadmap) - [Performance Highlights](https://pharmaniaga.com/sustainability/#performance-highlights) - [Our Material Sustainability Matters](https://pharmaniaga.com/sustainability/#material-matters) - [Reports](https://pharmaniaga.com/sustainability/#reports) - [Media](https://pharmaniaga.com/) - [Media Centre](https://pharmaniaga.com/media-centre/) - [Press Releases](https://pharmaniaga.com/press-releases-2/) - [Gallery](https://pharmaniaga.com/media-centre/gallery/) - [Career](https://pharmaniaga.com/careers/) - [Career Opportunities](https://pharmaniaga.com/careers/) - [Graduates (Pharmagrad)](https://pharmaniaga.com/wp-content/uploads/2024/04/PDF-PharmaGrad.pdf) - [Job Scams](https://pharmaniaga.com/job-scams/) - [Supplier Relations](https://pharmaniaga.com/) - [Tender List](https://pharmaniaga.com/tender-list/) - [Vendor Registration](https://pharmaniaga.com/vendor-registration/) - [Contact Us](https://pharmaniaga.com/contact-us/) - [General Enquiries](https://pharmaniaga.com/contact-us/) - [Help & Feedback](https://pharmaniaga.com/enquiries/) - [Whistleblowing](https://pharmaniaga.com/about-us/corporate-policies/) - [About Us](https://pharmaniaga.com/) - [Who We Are](https://pharmaniaga.com/about-us/who-we-are/) - [Corporate Policies](https://pharmaniaga.com/about-us/corporate-policies/) - [Corporate Structure](https://pharmaniaga.com/about-us/corporate-structure/) - [Leadership](https://pharmaniaga.com/about-us/leadership-2/) - [Milestones](https://pharmaniaga.com/milestones/) - [Awards & Recognitions](https://pharmaniaga.com/about-us/awards-recognitions/) - [Standards & Certifications](https://pharmaniaga.com/standards-certifications/) - [Products & Services](https://pharmaniaga.com/) - [Products](https://pharmaniaga.com/) - [Pharmaceutical](https://pharmaniaga.com/product/pharmaceutical-3/) - [Services](https://pharmaniaga.com/services/) - [Logistics & Distribution](https://pharmaniaga.com/services/logistics-and-distribution/) - [Manufacturing](https://pharmaniaga.com/services/manufacturing/) - [Medical Equipping](https://pharmaniaga.com/services/medical-equipping/) - [Research & Development](https://pharmaniaga.com/services/research-and-development/) - [Customer Care](https://pharmaniaga.com/customer-care) - [Indonesia Operation](https://pharmaniaga.com/services/indonesia-operations-2/) - [Distributorship](https://pharmaniaga.com/distributorship) - [Approved Products Purchased List](https://catalogv2.pharmaniaga.com/) - [Investor Relations](https://pharmaniaga.com/investor-relations-2/) - [Corporate Information](https://pharmaniaga.com/investor-relations-2/corporate-information/) - [Corporate Governance](https://pharmaniaga.com/investor-relations-2/corporate-governance-2/) - [Stock Information](https://pharmaniaga.com/investor-relations-2/stock-information/) - [Financial Information](https://pharmaniaga.com/investor-relations-2/financial-information/) - [Investor Resources](https://pharmaniaga.com/investor-relations-2/investor-resources/) - [News Centre](https://pharmaniaga.com/investor-relations-2/news-centre/) - [Reports](https://pharmaniaga.com/investor-relations-2/reports/) - [Sustainability](https://pharmaniaga.com/sustainability/) - [ESG Profile](https://bit.ly/3v5ldxl) - [Our Sustainability Missions](https://pharmaniaga.com/sustainability/#our-sustainability-mission) - [Sustainability Roadmap](https://pharmaniaga.com/sustainability/#sustainability-roadmap) - [Performance Highlights](https://pharmaniaga.com/sustainability/#performance-highlights) - [Our Material Sustainability Matters](https://pharmaniaga.com/sustainability/#material-matters) - [Reports](https://pharmaniaga.com/sustainability/#reports) - [Media](https://pharmaniaga.com/) - [Media Centre](https://pharmaniaga.com/media-centre/) - [Press Releases](https://pharmaniaga.com/press-releases-2/) - [Gallery](https://pharmaniaga.com/media-centre/gallery/) - [Career](https://pharmaniaga.com/careers/) - [Career Opportunities](https://pharmaniaga.com/careers/) - [Graduates (Pharmagrad)](https://pharmaniaga.com/wp-content/uploads/2024/04/PDF-PharmaGrad.pdf) - [Job Scams](https://pharmaniaga.com/job-scams/) - [Supplier Relations](https://pharmaniaga.com/) - [Tender List](https://pharmaniaga.com/tender-list/) - [Vendor Registration](https://pharmaniaga.com/vendor-registration/) - [Contact Us](https://pharmaniaga.com/contact-us/) - [General Enquiries](https://pharmaniaga.com/contact-us/) - [Help & Feedback](https://pharmaniaga.com/enquiries/) - [Whistleblowing](https://pharmaniaga.com/about-us/corporate-policies/)      ## **WHAT WE DO**   [](https://pharmaniaga.com/services/logistics-distribution/malaysia/)   [View all Our Businesses](https://pharmaniaga.com/services/) #### **Sustainability** #### **is deep rooted in all** #### **our decision making** We always strive to do more in order to positively impact our patients consumers, employees, communities as well as our shareholders. We firmly believed that doing business with a conscience is integral in order to sustain our business success. [Discover more](https://pharmaniaga.com/sustainability/)   LATEST #### **News Updates** 16 MARCH 2026 [**PHARMANIAGA EXITS PN17 STATUS, HERALDS NEW PERIOD OF GROWTH AND STABILITY**](https://pharmaniaga.com/wp-content/uploads/2026/03/260316-Pharmaniaga-Press-Release-Upliftment-of-PN17-final-effective-17-Mar.pdf) Pharmaniaga Berhad (“Pharmaniaga” or “the Group”) today announced the successful upliftment of its Practice Note 17 (PN17) status by Bursa Malaysia Securities Berhad (“Bursa”), effective tomorrow. This marks a significant key milestone in the Group’s recovery and renewed growth trajectory. 23 FEBRUARY 2026 [**PHARMANIAGA DELIVERS EIGHT CONSECUTIVE PROFITABLE QUARTERS, REINFORCING MOMENTUM TOWARDS PN17 EXIT**](https://pharmaniaga.com/wp-content/uploads/2026/02/Pharmaniaga-Q4FY2025-Press-Release-v17.pdf) Pharmaniaga Berhad (Pharmaniaga or the Group) recorded a Profit After Tax (PAT) of RM8.7 million for the fourth quarter ended 31 December 2025 (Q4FY2025), marking its eight consecutive profitable quarter and strengthening the Group’s financial recovery and momentum towards exiting PN17. 13 NOVEMBER 2025 [**PHARMANIAGA RECORDS SEVENTH CONSECUTIVE PROFITABLE QUARTER, REINFORCING PATH TO EXIT PN17 STATUS**](https://pharmaniaga.com/wp-content/uploads/2025/11/PHARMANIAGA-RECORDS-SEVENTH-CONSECUTIVE-PROFITABLE-QUARTER-REINFORCING-PATH-TO-EXIT-PN17-STATUS.pdf) Pharmaniaga Berhad (Pharmaniaga or the Group) continues to sustain its positive momentum towards exiting PN17 status, marking its seventh consecutive profitable quarter for the period ended 30 September 2025 (Q3 FY2025). This achievement underscores the Group’s resilient operational capabilities and steady business recovery trajectory. 26 AUGUST 2025 [**PHARMANIAGA MAINTAINS UPWARD MOMENTUM IN Q2 FY2025, REINFORCING TURNAROUND STRATEGY**](https://pharmaniaga.com/wp-content/uploads/2025/08/Press_Release_Q2_final.pdf) Pharmaniaga Berhad (Pharmaniaga or the Group) continues its positive momentum in the second quarter of its financial year ended 30 June 2025 (Q2 FY2025), marking key milestones across its financial, pharmaceutical, and logistics segments. Reinforcing its steady progress towards exiting Practice Note 17 (PN17) status, the Group recorded a Profit After Taxation (PAT) of RM4.2 million, a 9.5% increase from RM3.8 million posted in the corresponding quarter of the previous financial year (Q2 FY2024). 6 AUGUST 2025 [**PHARMANIAGA COMPLETES REGULARISATION PLAN, SETS COURSE TO EXIT PN17 BY Q1 2026**](https://pharmaniaga.com/wp-content/uploads/2025/08/PR_RP_completion_V7.pdf) Pharmaniaga Berhad (Pharmaniaga or the Group) has successfully completed its third and final critical milestone of its Regularisation Plan (RP), the Capital Reduction exercise, hence completed the RP and fully compliant with the Main Market Listing Requirements of Bursa Malaysia, a significant step that firmly sets the Group on course to exit Practice Note 17 (PN17) status latest by the first quarter of 2026. [OLDER NEWS](https://pharmaniaga.com/press-releases-2/) ## **INTEGRATED** ## **REPORT** ## **2024** [DOWNLOAD REPORT HERE](https://pharmaniaga.com/wp-content/uploads/2025/05/WEBSITE-PHARMANIAGA-BERHAD-IAR2024_Single.pdf) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ ## SUSTAINABILITY ## **REPORT 2022** [DOWNLOAD REPORT HERE](https://www.insage.com.my/Upload/Docs/PHARMA/PHARMANIAGA%20SR%20FINAL%20110523_Web.pdf#view=Full) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ ##### PHARMANIAGA BERHAD Established in 1994, Pharmaniaga has evolved to become one of Malaysia’s largest listed integrated pharmaceutical groups. Our participation in the sector spans across the pharmaceutical value chain from research and development to the production of generic drugs, over-the-counter medicines, logistics and distribution, sales and marketing. In 2021, we made history by becoming the first Malaysian pharmaceutical company to fill and finish manufacture a human vaccine. Already a formidable player in the domestic market, we continue to explore the strategic expansion of our international reach. ##### GROW WITH US Explore career opportunities with Pharmaniaga. [Recruitment](mailto:recruitment@pharmaniaga.com) [Training / Internship](mailto:pharma_training@pharmaniaga.com) ##### PHARMACOVIGILANCE / DRUG SAFETY [drugsafetyunit@pharmaniaga.com](mailto:drugsafetyunit@pharmaniaga.com) [Toll free : 1-800-888-313](tel:1800888313) [Tel : 03-3342 9999](tel:0333429999) ##### WHISTLEBLOWING Our whistleblowing channel is as below : Dr Abdul Razak Ahmad (Senior Independent Non-Executive Director) [razak.ahmad@pharmaniaga.com](<font-family: italic; mailto: razak.ahmad@pharmaniaga.com>) Sarah Azreen Abdul Samat (Chairman of Audit Committee) [sarah.samat@pharmaniaga.com](<mailto: sarah.samat@pharmaniaga.com>) Integrity & Governance Unit [whistleblow@pharmaniaga.com](mailto:whistleblow@pharmaniaga.com) [Hotline : 1 800 182 082](tel:1800182082) ##### CUSTOMER CARE [Toll free : 1 800 888 313](tel:1800888313) [contactcentre@pharmaniaga.com](mailto:contactcentre@pharmaniaga.com) ##### OUR SERVICES [Research & Development](https://pharmaniaga.com/services/research-and-development/) [Manufacturing](https://pharmaniaga.com/services/manufacturing/) [Medical Equipping](https://pharmaniaga.com/services/medical-equipping/) [Logistics & Distribution](https://pharmaniaga.com/services/logistics-and-distribution/) [Customer Care](https://pharmaniaga.com/services/customer-care/) [Distributorship](https://pharmaniaga.com/services/distributorship/) [Indonesia Operations](https://pharmaniaga.com/services/indonesia-operations-2/) ##### OUR PRODUCTS [Pharmaceuticals](https://pharmaniaga.com/pharmaceutical/) [Medical Equipment](https://pharmaniaga.com/medical-equipment-product/) [Medical Consumables](https://pharmaniaga.com/medical-consumable-product/) [Medical Devices (Topical)](https://pharmaniaga.com/medical-devices-topical/) [Approved Product Purchased List](https://catalogv2.pharmaniaga.com/) ##### CONTACT US No.7, Lorong Keluli 1B, Kawasan Perindustrian Bukit Raja Selatan, Seksyen 7, 40000 Shah Alam, Selangor Darul Ehsan. Tel: [03-3342 9999](tel:+60333429999) Fax: [03-3341 7777](tel:+60333417777) [Enquiries](https://pharmaniaga.com/enquiries/) [Investor Relations](https://pharmaniaga.com/investor-relations-2/) [Media Centre](https://pharmaniaga.com/media-centre/) [e-Office](https://pharmaniaga.com/e-office/) © 2026 Pharmaniaga Berhad 199801011581 (467709-M). All Rights Reserved.

LATEST **News Updates** 16 MARCH 2026 Pharmaniaga Berhad (“Pharmaniaga” or “the Group”) today announced the successful upliftment of its Practice Note 17 (PN17) status by Bursa Malaysia Securities Berhad (“Bursa”), effective tomorrow. This marks a significant key milestone in the Group’s recovery and renewed growth trajectory. 23 FEBRUARY 2026 Pharmaniaga Berhad (Pharmaniaga or the Group) recorded a Profit After Tax (PAT) of RM8.7 million for the fourth quarter ended 31 December 2025 (Q4FY2025), marking its eight consecutive profitable quarter and strengthening the Group’s financial recovery and momentum towards exiting PN17. 13 NOVEMBER 2025 Pharmaniaga Berhad (Pharmaniaga or the Group) continues to sustain its positive momentum towards exiting PN17 status, marking its seventh consecutive profitable quarter for the period ended 30 September 2025 (Q3 FY2025). This achievement underscores the Group’s resilient operational capabilities and steady business recovery trajectory. 26 AUGUST 2025 Pharmaniaga Berhad (Pharmaniaga or the Group) continues its positive momentum in the second quarter of its financial year ended 30 June 2025 (Q2 FY2025), marking key milestones across its financial, pharmaceutical, and logistics segments. Reinforcing its steady progress towards exiting Practice Note 17 (PN17) status, the Group recorded a Profit After Taxation (PAT) of RM4.2 million, a 9.5% increase from RM3.8 million posted in the corresponding quarter of the previous financial year (Q2 FY2024). 6 AUGUST 2025 Pharmaniaga Berhad (Pharmaniaga or the Group) has successfully completed its third and final critical milestone of its Regularisation Plan (RP), the Capital Reduction exercise, hence completed the RP and fully compliant with the Main Market Listing Requirements of Bursa Malaysia, a significant step that firmly sets the Group on course to exit Practice Note 17 (PN17) status latest by the first quarter of 2026. [OLDER NEWS](https://pharmaniaga.com/press-releases-2/)